127 Durable Treatment of Painful Diabetic Neuropathy With 10 kHz Spinal Cord Stimulation
Erika A. Petersen,Thomas Stauss,James Scowcroft,Michael Jaasma,Judith White,Shawn Sills,Kasra Amirdelfan,Maged Guirguis,Jijun Xu,Cong Yu,Ali Nairizi,Denis Patterson,Vincent Galan,Richard Bundschu,Neel Mehta,Dawood Sayed,Nandan P. Lad,David DiBenedetto,Michael Creamer,Paul Wu,Charles Argoff,Christian Nasr,Rod S. Taylor,David Caraway,Nagy Mekhail
DOI: https://doi.org/10.1227/neu.0000000000002809_127
IF: 5.315
2024-04-01
Neurosurgery
Abstract:INTRODUCTION: Approximately 25% of people with diabetes experience painful diabetic neuropathy (PDN), but conventional medical management (CMM) is ineffective for many patients. We previously presented partial study results showing that high-frequency (10 kHz) spinal cord stimulation (SCS) provides substantial symptom relief. Here we report full study results through 24-month (24M) follow-up. METHODS: We conducted a multicenter RCT to evaluate 10 kHz SCS in PDN patients. Key study inclusion criteria were: PDN symptoms = 12M refractory to medications, lower limb pain intensity = 5cm (0-10 cm visual analog scale [VAS]), and hemoglobin A1c = 10%. Patients (n = 216) were randomized 1:1 to 10 kHz SCS plus CMM or CMM alone, with optional treatment crossover at 6M. RESULTS: Patients randomized to 10 kHz SCS experienced significantly greater pain relief at 6M than those treated with CMM alone (p < 0.001). For all patients who received 10 kHz SCS, at 24M post-implantation the average pain relief was 80% from pre-implantation (p < 0.001), and the treatment responder rate was 90%. Clinician-assessed sensory function showed significant improvements with 10 kHz SCS. At 6M, 59% of patients treated with 10 kHz SCS had sensory improvement versus 9% of those treated with CMM alone (p < 0.001). At 24M, 10 kHz SCS improved sensory function for 65% of patients. Patients receiving 10 kHz SCS also experienced significant improvements in health-related quality of life (HRQoL, p < 0.001). At 24M, the mean HRQoL improvement was 2.9-4.8 times the minimum clinically important difference for patients with type 2 diabetes. CONCLUSIONS: The results demonstrate that 10 kHz SCS provides significant, durable reductions in pain and improvements in sensory function and HRQoL. Sensory function improvements support the unique disease-modifying potential of 10 kHz SCS.
surgery,clinical neurology